Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 221 UK small molecule drug companies below.
Natural product-inspired small molecules for sexual and mental health
Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug…
Small molecule drug discovery targeting rare genetic diseases and oncology
Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic…
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines.…
Clinical-stage antifungal drug developer targeting invasive fungal infections
F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved…
Investigational oral ketamine formulations for treatment-resistant depression
Neurocentrx Pharma is a clinical-stage biopharmaceutical company developing oral ketamine formulations for treatment-resistant mood disorders. Its NRCx-201 programme includes immediate-release and abuse-deterrent capsules intended for clinically supervised treatment and potentially supported home care. Following…
Small-molecule HO-1 inhibitors to overcome chemotherapy resistance in tumours
Aethox Therapeutics is a preclinical biotechnology company developing small-molecule drugs that help solid tumours respond to chemotherapy and other standard cancer treatments. Its lead approach targets heme oxygenase-1 (HO-1), an enzyme produced by tumour-associated macrophages that can block cancer-fighting T cells…
Transformative medicines for cystic fibrosis and serious genetic diseases
Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has…
Pharmaceutical formulation development and clinical manufacturing services
SGS Quay Pharma is a contract development and manufacturing organisation providing formulation development, analytical services, and clinical trial manufacturing for pharmaceutical and biotechnology companies. The company specialises in dosage form design for APIs with challenging solubility and bioavailability…
Pharmaceutical development, clinical pharmacology and GMP manufacturing
Seda Pharmaceutical Development Services is a provider of integrated pharmaceutical development, clinical pharmacology and GMP manufacturing services to the pharma and biotech sectors. The company supports clients from early-stage drug development through clinical trials to regulatory approval, with particular…
Specialist CRO for inhaled and nasal drug product development
Nanopharm is a contract research organisation specialising in the development of orally inhaled and nasal drug products, providing formulation development, materials characterisation, analytical testing, and in vitro and in silico modelling services to pharmaceutical and biotechnology clients. The company supports…
Small molecule inhibitors targeting APOBEC enzymes in cancer
Apobec Discovery is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors of APOBEC3A and APOBEC3B, cytidine deaminase enzymes that drive tumour mutagenesis, evolution, and resistance to treatment. By blocking APOBEC activity, the company aims to limit the mutational capacity of…
Novel small-molecule therapeutics for neurodegenerative diseases
Nevrargenics is a UK-based biotech company developing novel small-molecule therapeutics for neurodegenerative diseases. Spun out of Durham University and built on research collaboration with the University of Aberdeen, the company uses a patented library of dual-activity retinoic acid receptor modulators designed to…
Clinical-stage therapeutics for advanced liver disease
Yaqrit is a clinical-stage biotechnology company developing treatments for patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure. Its pipeline includes an oral ammonia scavenger for hepatic encephalopathy, an extracorporeal liver support device, and a microbiome-based…
Micellar oral cannabidiol formulation for psychiatric drug development
NWPharmaTech is a clinical-stage biotechnology company developing investigational oral cannabidiol formulations for psychiatric disorders. Its NWPT-SM32300 programme uses a high-loading micellar softgel intended to deliver consistent oral doses. The company reports completion of a Phase 1 pharmacokinetic and…
Multimodal small molecule therapeutics for neurodegenerative disease
Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously,…
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers.…
Oncology biotech developing peptide therapeutics and diagnostics
ValiRx is a UK-listed biopharmaceutical company focused on the development of oncology therapeutics and companion diagnostics. The company selects and incubates novel drug candidates, including peptide-based compounds targeting prostate cancer, endometriosis, and other solid tumours, progressing them from preclinical…
Chiral and achiral chromatography services for small molecule purification
Reach Separations is a contract chromatography company specialising in the analysis and purification of small molecules for clients in the pharmaceutical, agrochemical, and fine chemical sectors. Using HPLC and SFC technologies, the company provides chiral and achiral separation services from discovery scale through…
Biomarker-guided therapeutics for psychosis-related cognitive impairment
Monument Therapeutics is a clinical-stage biopharmaceutical company developing stratified treatments for neuropsychiatric conditions. Its lead programme, MT1988, is being evaluated in people at clinical high risk of psychosis. A randomised, placebo-controlled Phase 1/2 study dosed its first participant in March 2026…
Small molecules improving ribosomal translation accuracy in ageing cells
Ribogenyx is a biotechnology company developing small-molecule therapies to improve protein synthesis accuracy in ageing cells. Its approach targets translational fidelity, the accuracy with which ribosomes translate messenger RNA into proteins. By reducing production errors, the company aims to preserve protein…